Parkinnova Therapeutics

Parkinnova Therapeutics B.V. is a biotechnology company spun off from the University of Amsterdam in January 2024, focusing on the development of novel treatments for Parkinson's disease. The company was established by Professor Dr. Marten P. Smidt and Dr. Lars P. van der Heide, both recognized experts in molecular neuroscience with extensive experience in the pathophysiology of the disorder. Their research background in the dopaminergic cells affected by Parkinson's directly informs the company's scientific direction. Located at the Amsterdam Science Park, Parkinnova aims to translate fundamental scientific insights into commercially viable therapies.

The company's core focus is on developing a dual-action therapeutic approach for Parkinson's disease. This strategy is centered on inhibiting PDE11A, an enzyme found in the dopamine cells implicated in the disease. The goal is to provide both symptomatic relief and neuroprotective effects, thereby slowing or even halting the progression of the disease. This contrasts with many current treatments that primarily address symptoms without affecting the underlying neurodegeneration. Parkinnova is advancing a new generation of PDE inhibitors, optimizing their molecular properties, and conducting extensive preclinical testing to validate efficacy and safety for future clinical development. The company's intellectual property includes patents for increasing dopamine synthesis and for using PDE11 and PDE2 inhibitors.

Parkinnova Therapeutics operates within the biotechnology and pharmaceutical research sector, specifically targeting the global market for Parkinson's disease treatments. Its business model is predicated on the research, development, and eventual commercialization of its proprietary drug candidates. The company's clients would be larger pharmaceutical companies for potential licensing deals or partnerships, and ultimately, healthcare systems and patients upon successful drug approval. As a venture capital-backed entity, the company has secured funding to advance its preclinical programs. A significant milestone was receiving a €350,000 convertible loan from Innovatiefonds Noord-Holland in April 2025 to further its research and development efforts.

Keywords: Parkinson's disease treatment, neuroprotection, dopamine synthesis, PDE inhibitors, PDE11A, molecular neuroscience, biotech spin-off, preclinical research, neurodegenerative disease therapy, University of Amsterdam, Amsterdam Science Park, Marten Smidt, Lars van der Heide, therapeutic development, drug discovery, motor symptoms, disease modification, neuropharmacology, biotechnology, life sciences